The document discusses the new roles and responsibilities of medical editors in the age of Big Data. It outlines the traditional roles of editors in overseeing peer review and setting editorial standards. It also describes how editors now evaluate different types of large dataset submissions, such as those involving genomics, transcriptomics, and epidemiology. The document suggests that future roles of editors may involve greater transparency through enforcing data sharing plans and pre-publishing results summaries.
Call Girls in Sarai Kale Khan Delhi 💯 Call Us 🔝9205541914 🔝( Delhi) Escorts S...
Rebecca E. Cooney MedicReS World Congress 2015
1. The new roles and responsibilities of
medical editors in the age of Big Data
Rebecca E. Cooney, PhD
North American Editor
The Lancet
@BekRx #LancetUSA
October 19-25 | 2015 New York
www.medicres.org
2. The Lancet
• Established in 1823
• Editorial offices in London, New York, and Beijing
• Weekly publication
• Impact factor = 45.217
• 9 “daughter journals” + EBioMedicine
Diabetes & Endocrinology
Global Health
Infectious Diseases
Neurology
Oncology
Respiratory Medicine
HIV
Haematology
Psychiatry
October 19-25 | 2015 New York
www.medicres.org
6. Overview
• What are the roles and responsibilities of a
medical editor in general?
• The lifecycle of a publication
• Evaluating a manuscript
• Evaluating findings
• Focus on clinical trials, protocols, reporting
• Transparency
• What might the future look like – IOM report,
PCORI October 19-25 | 2015 New York
www.medicres.org
7. What do editors do?
October 19-25 | 2015 New York
www.medicres.org
8. What do editors do?
October 19-25 | 2015 New York
www.medicres.org
The Midwife
9. The role of professional editors
•To oversee the peer review process,
facilitate effective dialogue between
authors and reviewers, and ensure
process is efficient and productive.
•To set editorial policy and standards for
the journal.
•To keep abreast of advances in the field.
•Editorial writing, commissioning reviews or series,
attending conferences, meeting with KOLs, interacting
with the media
12. When a manuscript is submitted
• The paper is read by the editor. The editor
will review the published literature to
assess whether the present work
represents a significant conceptual
advance.
• This editor will handle the paper
throughout the review process. Papers are
also discussed with the team of editors at
editorial meetings.
13. What kind of manuscript
submissions are we seeing?
October 19-25 | 2015 New York
www.medicres.org
14. The Omics
• Genomics
– Nucleotide genome sequences, metagenomic sequences
– Gene finding, functional annotation, sequence alignment, homology
determination, comparative analysis, phylogenetic inferencing, association
analysis, mutation functional prediction, species distribution analysis
• Transcriptomics
– RNA expression levels, transcription factor binding, chromatin structure
information
– Differential expression, clustering, functional enrichment, transcriptional
regulation/causal reasoning
• Proteomics
– Proteins levels, protein structures, protein interactions
– Protein identification, protein functional predictions, structural predictions,
structural comparison, molecular dynamic simulation, mutation functional
prediction, docking predictions, network analysis
• Metabolomics
– Metabolite/small molecule levels
– Pathway/network analysis
October 19-25 | 2015 New York
www.medicres.org
15. Other kinds of Big Data
submissions
• Surveillance - detection of Ebola and other
emerging infectious diseases
• Risk factors – trajectories of cardiometabolic
risk factors
• Epidemiology – Global Burden of Disease
studies published with IHME
October 19-25 | 2015 New York
www.medicres.org
17. What we look for
• Does the study ask an interesting and important
question?
• Does it provide a significant conceptual advance
beyond what was already known? Does it change
the way we think about a field, process, or particular
issue in some way?
• From The Lancet author page: “advances or
illuminates medical science or practice, or that
educates or entertains the journal's readers”
• Are the experiments logically designed? Is this the
right experiment to answer this question?
• Is the paper well presented for a broad audience?
18. Clinical trial reporting
• Protocol review
• Consolidated Standards of Reporting Trials
http://www.consort-statement.org/
October 19-25 | 2015 New York
www.medicres.org
19. The outcome of initial editorial
evaluation
1) Return the manuscript to the authors
with an explanation of why the editors feel it is
not likely to be a strong candidate for
publication
2) Send the paper out for review
The editors identify appropriate reviewers,
taking into consideration author suggestions and
exclusions
20. The peer review process
• We ask reviewers to provide comments
on technical competence and on
whether the paper provides a
sufficiently significant conceptual
advance
• Reviewers can make confidential
remarks to the editor as well as
providing a report for the authors.
21. Why does it take so long?
21
Stage Time (in days)
Submission to editor assignment 3.2
Editor assignment to reviewer invitation 6.6
Reviewer invitation to reviewer response 4.7
Reviewer agreement to review
completion
12.1
Submission to first decision 42.6
Stage Time (in days)
Submission to editor assignment 2.4
Editor assignment to reviewer invitation 13.1
Reviewer invitation to reviewer response 1.0
Reviewer agreement to review
completion
17.5
Submission to first decision 34.8
Journal X
Journal Y
22. What we look for in a reviewer’s
report
• A clear, concise summary of the conceptual ‘take
home’ message of the paper, and whether this
presents an exciting advance for the field
• The key technical concerns and how these could be
addressed
• Any minor technical issues (if recommending
revision)
• A recommendation whether further experiments that
can be completed in a timely fashion would make the
paper appropriate
23. When the reviews come back
• Reviewers don’t always agree, the ultimate decision
is not a simple count of votes “for” and “against”.
• The editor evaluates the reviewers’ comments and
decides in collaboration with team, and sometimes
in further consultation with reviewers, whether to
invite a revised version of the paper
• Our goal as editors is to communicate the decision
and the grounds for the decision to the authors
clearly and constructively.
24. When you receive the decision letter
• Focus on the scientific issues and what will
help you improve the paper
• If the reviews or editorial evaluation cite
legitimate limitations or lack of sufficient
general interest, it is usually in your best
interest to submit the manuscript to another
journal.
• If the reviewers and/or the editors have
misunderstood a key aspect of the paper,
consider an appeal
• With resubmission, provide a detailed point-
by-point response to reviewers’ comments
33. Transparency
• Data sharing plan requirement
• More sophisticated deidentification
• Uniformity requirements for metadata
• Allowing other PIs data to allow for secondary
analyses
• IOM Report on Data Sharing
https://iom.nationalacademies.org/Activities/
Research/SharingClinicalTrialData.aspx
October 19-25 | 2015 New York
www.medicres.org
34. Some final thoughts
• Should editors be the gatekeepers?
• How might pre-publication summary level
results and lay summaries affect traditional
peer-review publishing?
• Lay summaries as part of the finished product
of a publication?
• Whose responsibility will it be to store all
those data? Who will have access? How do we
protect patients?
October 19-25 | 2015 New York
www.medicres.org
This visual gives you a better idea of the journal publishing cycle and the different steps along the way.
Let me first go into the submissions and peer review steps in the cycle.
These are average processing times for two actual journals, both in the same STM field (and remember, the averages can vary quite significantly from field to field).
In Journal X, we see slightly more time spent on the initial check by the editorial office, as well as the reviewers taking longer to respond to invitations. In Journal Y, while the Editor takes longer to invite the first reviewers and the reviewers take longer to complete their reviews, the overall time from submission to first decision is more than a week shorter. What does this mean? In Journal X, we see a more typical pattern – reviewers take a few days to respond and only about half of them agree, whereas a quarter of the invited reviewers never respond. Maybe they’re too busy or away from their offices, maybe the manuscripts aren’t a great fit for their expertise. Editors try to be mindful of reviewers’ time and the fact that they are volunteers. Some journals invite more reviewers than they need at any one time, knowing that only about half will accept. Matters are complicated, too, if the reviewers don’t agree with each other. While the decision is ultimately the Editor’s, he/she may choose to seek additional reviews before making that decision.
So now your manuscript has been accepted. The next major steps in the journal publishing cycle are the editing, preparation and production stages.
The article production process is usually more complex than most people think and includes many steps along the way.
After the manuscript is accepted via peer review, publishers undertake the copyediting, proofing, formatting, branding, pagination, and logo affiliation. These tasks are not as simple as might be expected. Metadata and identifiers need to be added to papers. Artwork quality needs to be checked and enhanced. The manuscript needs to be converted to XML and the artwork needs to be converted. The text itself needs to be edited, structured and enhanced. Authors need to check, correct and approve the proofs.
Publishers can create an Electronic Warehouse and other electronic production tools to quicken production times. An XML format of the article is deposited in the Electronic Warehouse and from here, the article can then be published as an online HTML or PDF or it can be published as a print copy.
Next, comes the dissemination stage, a task that has been affected dramatically by the digital age.
Although traditionally scientific research has been communicated through print journals, by far most readers find and use the information they need online.
Elsevier created ScienceDirect as our institutional platform. Not only does a platform like ScienceDirect allow for someone to access articles from ANY of our journals, it also allows us to develop productivity enhancing solutions like linking between articles and references, searching for articles, and providing lists of related articles.
In addition, many of our journals maintain their own separate websites for personal subscribers, such as society members.
The online version can offer options that are not available in the print version. The best options vary from discipline to discipline and article type to article type, but some examples include ScienceDirect’s Protein Viewer, Genome Viewer and Google Maps features.
But an article’s online presence does not stop with electronic journal platforms.
Many publishers are experimenting with other methods of dissemination such as advertising-supported models. In Elsevier’s case, we have created a portal called PracticeUpdate. This portal aims to connect healthcare professionals with news and information from different sources such as journal articles, expert commentaries, conference coverage and news.
Podcasts and social media. We’ll talk more about this later. Our flagship journal, The Lancet, offers podcast summaries of issues, mobile feeds of articles, and blogs of the latest research initiatives.
And finally, especially for point-of-care reference, scientific information can be effectively delivered via apps.
Finally, let me touch up on the last step in the journal publishing cycle: archiving and promoting the use of the articles (we’ll talk about that in greater detail later).